SRR650188
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.420
- MITOTIC_SPINDLE+0.350
- TGF_BETA_SIGNALING+0.350
- PROTEIN_SECRETION+0.240
- MYC_TARGETS_V2+0.230
- PI3K_AKT_MTOR_SIGNALING+0.140
- P53_PATHWAY+0.130
- NOTCH_SIGNALING+0.120
- APICAL_SURFACE+0.090
- DNA_REPAIR+0.090
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.560
- ANGIOGENESIS-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- INFLAMMATORY_RESPONSE-0.380
- IL6_JAK_STAT3_SIGNALING-0.370
- ALLOGRAFT_REJECTION-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- INTERFERON_GAMMA_RESPONSE-0.320
- MYOGENESIS-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650135 | — | — | 0.851 |
| 2 | SRR650200 | — | — | 0.847 |
| 3 | SRR15030890 | — | — | 0.833 |
| 4 | SRR33346954 | — | — | 0.814 |
| 5 | A130FABA-F55F-412D-940E-7305057B4D1A | — | — | 0.800 |
| 6 | MNG892 | — | — | 0.794 |
| 7 | MDT-AP-1138 | Med | Medulloblastoma | 0.784 |
| 8 | SRR13311175 | — | — | 0.784 |
| 9 | MDT-AP-3246 | Med | Medulloblastoma | 0.783 |
| 10 | MDT-AP-3315 | Med | Medulloblastoma | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |